Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort BA MDI vs pMDI in Asthma
NCT01360021Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2011
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of budesonide in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: Forced Expiratory Volume in 1 Second (FEV1) - Post Dose and Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose. Started Nov 2011; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01360021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360021.